Companies › Sitala Bio
1 active drug program in 2 registered trials: 2 Phase 2; Genitourinary, Ophthalmology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STL303 | – | Phase 2 | IgAN; Geographic Atrophy | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07606352 | STL303 | Phase 2 | IgAN | Genitourinary | Jul 2027 |
| NCT07606365 | STL303 | Phase 2 | Geographic Atrophy | Ophthalmology | Jul 2028 |
No annotated target.
–
Vantage Biosciences Tioga Pharmaceuticals Tourmaline Bio, Inc., a Novartis Company Azure Biotech Sunhawk Vision Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.